Cargando…
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592884/ https://www.ncbi.nlm.nih.gov/pubmed/34816136 http://dx.doi.org/10.1016/j.jdin.2021.09.007 |
| _version_ | 1784599575420469248 |
|---|---|
| author | Lytvyn, Yuliya Mufti, Asfandyar Zaaroura, Hiba Sachdeva, Muskaan Lu, Justin D. Rankin, Brian D. Prajapati, Vimal H. Vender, Ronald Yeung, Jensen |
| author_facet | Lytvyn, Yuliya Mufti, Asfandyar Zaaroura, Hiba Sachdeva, Muskaan Lu, Justin D. Rankin, Brian D. Prajapati, Vimal H. Vender, Ronald Yeung, Jensen |
| author_sort | Lytvyn, Yuliya |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8592884 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85928842021-11-22 Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study Lytvyn, Yuliya Mufti, Asfandyar Zaaroura, Hiba Sachdeva, Muskaan Lu, Justin D. Rankin, Brian D. Prajapati, Vimal H. Vender, Ronald Yeung, Jensen JAAD Int Research Letter Elsevier 2021-11-09 /pmc/articles/PMC8592884/ /pubmed/34816136 http://dx.doi.org/10.1016/j.jdin.2021.09.007 Text en © 2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Research Letter Lytvyn, Yuliya Mufti, Asfandyar Zaaroura, Hiba Sachdeva, Muskaan Lu, Justin D. Rankin, Brian D. Prajapati, Vimal H. Vender, Ronald Yeung, Jensen Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title | Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title_full | Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title_fullStr | Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title_full_unstemmed | Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title_short | Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study |
| title_sort | efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: a 16-week canadian retrospective multicenter cohort study |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592884/ https://www.ncbi.nlm.nih.gov/pubmed/34816136 http://dx.doi.org/10.1016/j.jdin.2021.09.007 |
| work_keys_str_mv | AT lytvynyuliya efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT muftiasfandyar efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT zaarourahiba efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT sachdevamuskaan efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT lujustind efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT rankinbriand efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT prajapativimalh efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT venderronald efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT yeungjensen efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy |